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ABSTRACT 
 
 
 
Mycobacterium tuberculosis is the leading cause of death by an infectious disease 
(MacNeil, 2019). In 2018, 10 million people developed tuberculosis and half a million 
infections were resistant to antibiotics (WHO, 2019). Nearly all members of the M. 
tuberculosis complex are lysogens, meaning they carry prophage, or integrated viral 
genomes within the host genome (Fan et al., 2016). The non-pathogenic vaccine strain (M. 
bovis Bacillus Calmette–Guérin (BCG)) is the exception, which suggests prophage play a 
role in virulence (Fan et al., 2016). Because not all prophage encode obvious virulence 
genes, we hypothesize that prophage impact bacterial virulence by altering bacterial gene 
expression. By studying gene expression patterns in M. chelonae, a close relative of M. 
tuberculosis, in the presence and absence of prophage BPs, we determined prophage 
impact mycobacterial gene expression. Through RNAseq analysis of M. chelonae with or 
without prophage, we detected significant changes in expression of almost 8% of M. 
chelonae genes, including the gene whiB7, which is involved in antibiotic resistance. 
During lysogenic infection of M. chelonae the most highly expressed gene from the BPs 
prophage was the immunity repressor (gp33). To determine if viral gene products drive 
changes in expression of whiB7, strains of M. chelonae that express gp33 were created and 
gene expression and antibiotic resistance analyses were performed. Expression of gp33 did 
not alter expression of M. chelonae whiB7 nor antibiotic resistance. We are now 
investigating alternative hypotheses to explain how prophage alter whiB7 expression.
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 1 
INTRODUCTION 
 
 
 
Mycobacterium tuberculosis is one of the top ten leading causes of death globally 
(WHO, 2019) and is the leading cause of death by an infectious disease (MacNeil, 2019). 
In 2018, 10 million new cases of tuberculosis were diagnosed and 500,000 cases were 
deemed multidrug resistant (MDR) (WHO, 2019). Non-tuberculosis mycobacteria are 
becoming increasingly drug-resistant and there is a need for alternative therapeutics. M. 
abscessus, for example, is an emerging pathogen in cystic fibrosis patients, and is 
extremely difficult to treat as some isolates are completely resistant to available antibiotics 
(Bryant et al., 2013). In order to develop new treatments for pathogens such as M. 
tuberculosis and M. abscessus, we must understand their mechanisms of pathogenicity and 
virulence. One aspect of mycobacterial pathogenicity that is not well understood is the role 
of prophage. 
 Bacteriophage (phage) are viruses that infect bacteria, while prophage are phage 
genomes that have integrated into bacterial genomes, creating a bacterial cell called a 
lysogen (Hatfull, 2011). The lysogenic state is established and maintained via the 
expression of the prophage-encoded immunity repressor protein (Shimatake, H., 
Rosenberg, M., 1981). The repressor binds to specific DNA sequences within the phage 
genome to prevent transcription of phage lytic genes during lysogeny, and can bind to 
invading genomes of similar phage to confer superinfection immunity to its bacterial host 
(Brussow et al., 2004). Prophage may express additional genes that contribute to virulence 
and pathogenicity of the bacterial host.  For example, Escherichia coli O157:H7 only 
causes illness when a Shiga-like toxin is expressed from a prophage (Fang et al., 2017). 
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However, not all prophage encode obvious virulence factors. The virulent M. tuberculosis 
strain H37Rv carries two prophage, while the nonvirulent vaccine strain M. bovis BCG 
does not carry prophage (Fan et al., 2016). It is hypothesized the prophage impact the 
pathogenicity of their mycobacterial hosts, but how they do so is still unknown (Fan et al., 
2016). Given that there are no obvious virulence factors encoded by the prophage, it's 
possible that prophage alter expression of bacterial virulence genes. 
 The Molloy lab has determined that the prophage, BPs, significantly alters gene 
expression and antibiotic resistance of the non-tuberculosis mycobacterial pathogen, M. 
chelonae (Sampson et al., 2009). The presence of the BPs prophage causes differential 
expression of 7% of M. chelonae genes (Molloy, unpublished). Genes associated with 
antibiotic resistance, whiB7 and a padR-like transcription factor (referred to as padR), were 
significantly up- and down-regulated, respectively. WhiB7 is a transcription factor that 
upregulates a regulon of genes, many of which impact antibiotic resistance, and are 
conserved in all mycobacteria, including M. tuberculosis and M. abscessus (Burian et al., 
2012, Hess et al., 2017). PadR is a transcriptional regulator that negatively regulates genes 
that function in responding to environmental stressors, such as antibiotics or phenolic acid, 
and is itself down regulated upon cellular exposure to antibiotics or other toxic compounds 
(Park et al., 2017). The changes in whiB7 and padR expression may explain the increased 
resistance to antibiotics observed in BPs-M. chelonae lysogens relative to M. chelonae 
Wild-Type (WT). The BPs-M. chelonae lysogen has increased viability in the presence of 
antibiotics compared to that of the non-BPs lysogen, M. chelonae WT. It is not understood 
how the presence of BPs alters expression of whiB7 and padR. It is possible that genes 
expressed from the prophage genome, such as the immunity repressor, gp33, drive changes 
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in bacterial gene expression. The most highly expressed prophage-encoded gene during 
lysogenic infection of M. chelonae is the BPs immunity repressor, gp33 (Molloy, 
unpublished). If BPs gp33 is responsible for the changes we see in gene expression and 
antibiotic resistance during BPs lysogenic infection of M. chelonae, we should see similar 
changes in gene expression and antibiotic resistance profiles in a strain of M. chelonae 
expressing only BPs gp33 as observed in the BPs-M. chelonae lysogen.  
The goal of this project was to create a recombinant strain M. chelonae (pMHIR), 
that expresses the BPs immunity repressor, gp33, to determine if it is responsible for the 
changes in bacterial gene expression and antibiotic resistance observed in the BPs-M. 
chelonae lysogen.  Using an integrative vector, control and experimental recombinant 
strains of M. chelonae were constructed that express the BPs integrase alone or with a 
functional BPs immunity repressor. Integration of the plasmids into the bacterial genome 
was detected by PCR analysis and the ability of these strains to produce a functional 
repressor protein was tested by superinfection immunity assays. To measure the impact of 
repressor function on padR and whiB7 expression in the experimental and control 
recombinant strains, RNA was isolated and analyzed by qRT-PCR. To determine if the 
immunity repressor increases M. chelonae antibiotic resistance, minimum inhibitory 
concentration (MIC) assays were conducted on the recombinant strains in the presence of 
clarithromycin and tetracycline, antibiotics commonly used to treat mycobacterial 
infections.  
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LITERATURE REVIEW 
 
 
 
Pathogenic Mycobacteria 
Actinobacteria are one of the largest bacterial phyla and include numerous 
pathogens. Bacteria belonging to the Actinobacteria phylum are Gram-positive and have 
high G/C content in their genomes, meaning a majority of their genome is made up of 
guanine and cytosine nucleotides as opposed to adenine and thymine. (Barka et al., 2015). 
They are found in soil, fresh and marine waters, and man-made water distribution systems 
(Percival, 2014). One of the most important genera within the Actinobacteria is 
Mycobacterium, a genus that contains multiple pathogens (Percival, 2014). Mycobacteria 
include both obligate and opportunistic pathogens that cause pulmonary diseases, skin 
lesions, and abscesses (Percival, 2014).  
Mycobacteria cause more deaths worldwide than any other infectious agent (Bussi, 
2019). M. tuberculosis alone causes approximately 1.5 million deaths and 10 million new 
infections every year (WHO, 2019). Tuberculosis causes a pulmonary infection and 
presents as chest pain and a chronic cough that may expel blood or sputum (Zaman, 2010). 
Latent (asymptomatic) tuberculosis infects 25% of the population (MacNeil, 2019). Non-
tuberculosis mycobacteria (NTM) can also cause lung infections and account for 13% of 
lung infections in cystic fibrosis patients (Jones et al., 2019). Members of the M. abscessus 
complex cause skin and soft tissue infections, central nervous system infections, 
bacteremia, ocular infections and chronic respiratory disease (Lee et al., 2015). The M. 
abscessus complex is responsible for 80% of pulmonary infections caused by NTM (Daley, 
C. 2016). M. abscessus is an emerging pathogen in cystic fibrosis patients, and is extremely 
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difficult to treat as some isolates are completely resistant to available antibiotics (Bryant et 
al., 2013).  
M. chelonae is an ideal model for studying the more dangerous mycobacterial 
pathogens, such as M. abscessus and M. tuberculosis as it is pathogenic in humans and has 
high intrinsic antibiotic resistance (McFee, 2013). M. chelonae can cause disseminated skin 
disease, including cellulitis and abscesses, and can be acquired from contaminated water 
or infected surgical implantations (McFee, 2013). Based on multiple conducted studies, 
infections caused by the M. abscessus/M. chelonae group account for 3–13% of all 
pulmonary infections caused by mycobacteria (Lee et al., 2015). M. chelonae and M. 
abscessus were considered the same species until 1992 because of their high sequence 
similarity (Lee et al., 2015). The overall prevalence of M. abscessus/M. chelonae infections 
is increasing, as is their ability to become multidrug resistant (Jones et al., 2019). 
Prevalence of antibiotic resistant mycobacteria 
The incidence of antibiotic resistant mycobacteria is increasing due to the heavy 
use of antibiotics to treat bacterial, including mycobacterial, infections. For example, in 
2017, there were 10 million new cases of tuberculosis (MacNeil, 2019). Of all tuberculosis 
cases, 5.6% were deemed rifampicin resistant (RR) or multidrug-resistant (MDR), 
including 3.6% of new cases and 18% of previously diagnosed cases (MacNeil, 2019). 
Non-tuberculosis mycobacteria (NTM), including M. abscessus are resistant to almost all 
first-line drugs (Lee et al., 2015). The current treatment for M. abscessus infections 
includes a mix of the antibiotics clarithromycin, cefoxitin and amikacin, among others. 
However, amikacin resistance is growing, it is only about 50% effective, and has 
debilitating side effects (Hess et al., 2017). Understanding the underlying mechanisms of 
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how pathogenic mycobacteria are growing increasingly resistant to antibiotics is key to 
developing new therapeutics. 
Mycobacteria have various intrinsic properties that confer antibiotic resistance and 
make them difficult to treat (Nyugen, L., Thompson, C. 2006). For example, mycobacteria 
are known for their selectively permeable cell wall with an internal waxy barrier that limits 
the diffusion of hydrophobic and hydrophilic molecules, including antimicrobial agents 
(Nyugen, L., Thompson, C. 2006). Mycobacteria also encode genes that provide intrinsic 
antibiotic resistance and their expression is upregulated in the presence of sub-inhibitory 
concentrations of antibiotics, such as aminoglycosides (Nyugen, L., Thompson, C. 2006). 
Aminoglycosides bind to the 16s rRNA of the 30S ribosomal subunit, therefore mutations 
in the 16s rRNA change the ability of aminoglycosides to bind to the 30S ribosome 
(Zaunbrecher et al. 2009). Genes that confer antibiotic resistance include: efflux pumps, 
which transport drugs out of the cell through ABC transporters and facilitator proteins; 
antibiotic modifying enzymes; antibiotic degrading enzymes, and target-modifying 
enzymes (Nyugen, L., Thompson, C. 2006). Many of these genes belong to the WhiB7 
regulon, genes that are expressed in the presence of the transcription factor whiB7. 
 WhiB7 is an autoregulated transcriptional activator of resistance genes and belongs 
to the WhiB family of transcription factors that is conserved across Actinobacteria (Hess, 
2017). Expression of whiB7 is dependent upon one promoter approximately 350 – 450-bp 
upstream of the whiB7 gene in mycobacteria (Burian, 2018). Between the promoter and 
upstream of the whiB7 gene there is an open reading frame (uORF) that does not encode a 
functional protein (Burian, 2018). The uORF rather serves as a means of regulating 
transcript elongation across a transcriptional terminator sequence that is positioned 
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between the uORF and the whiB7 ORF (Burian, 2018). Transcription of the whiB7 ORF 
increases in the intracellular environment of the macrophage and with sub-inhibitory 
concentrations of antibiotics including tetracycline, fluoroquinolones, macrolides, and 
aminoglycosides (Nyugen, L., Thompson, C. 2006). Genes under the M. tuberculosis and 
M. abscessus WhiB7 regulon include erm, eis, and the tetV efflux pump (Burian, 2018, 
Hess et al., 2017). 
The Whib7 regulon in M. tuberculosis and M. abscessus includes a variety of genes 
that lead to resistance to aminoglycosides, macrolides, and tetracycline (Burian et al., 2012, 
Burian, 2018, Hess et al., 2017). erm is induced by macrolides, such as clarithromycin and 
azithromycin, and acts as a ribosomal RNA methyltransferase to prohibit macrolides from 
binding to sites in the 23S rRNA, thus preventing translation (Nyugen, 2006., Hess, 2017). 
Eis acetylates aminoglycosides, such as kanamycin and amikacin, which prevents the drugs 
from binding to the 30S rRNA subunit and inhibiting translation (Burian et al., 2012). M. 
abscessus contains two eis genes, both N-acetyl transferases, and eis2 is responsible for 
aminoglycoside resistance (Burian et al., 2012). Lastly, tap and tetV utilizes the proton 
motive force to work as an efflux pump to export aminoglycosides and tetracycline from 
the cytoplasm (Burian et al., 2012 (B)). Mechanisms of regulation of these antibiotic 
resistance genes are fairly well studied (Burian et al., 2012, Burian et al., 2012 (B), Burian, 
2018, Hess et al, 2017). Prophage are known to alter antibiotic resistance in some bacteria, 
but their role in regulating antibiotic resistance genes has not been studied (Wang et al., 
2010).  
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Bacteriophage and Prophage Characteristics 
Bacteriophage (phage), viruses that infect bacteria, are the most abundant 
biological entity with an estimated 1031 particles in the world (Hendrix, 2003). Viruses that 
infect bacteria of the genus Mycobacterium are termed mycobacteriophage and this 
population appears to also be incredibly abundant and incredibly diverse (Hatfull, 2014, 
Jacobs-Sera et a., 2012, Pope et al., 2011). To understand the relationships and evolution 
of phage, they are organized into clusters based on genome sequence identity and shared 
gene content (Pope et al., 2017). As of April 26th, 2020, there are 1,885 sequenced 
mycobacteriophage genomes belonging to 29 different clusters, 30 including singletons 
(Russell D., Hatfull, G. 2017). Some clusters of phage are well characterized and include 
clusters A, G, K, M, N, and O (Cresawn et al., 2015., Caratenuto et al., 2019., Sampson et 
al., 2009).  
Cluster G mycobacteriophage include 73 members that typically can infect multiple 
species of Mycobacterium including M. tuberculosis, M. smegmatis, M. abscessus and M. 
chelonae (PhagesDB, Jacobs-Sera, 2012; Molloy unpublished). The cluster includes 
members BPs, CLED96, Angel and Halo (Sampson et al., 2009; Russel et al., 2017). 
Cluster G phage are temperate, meaning they can carry out one of two growth cycles: the 
lytic or lysogenic cycle (Sampson et al., 2009). In the lytic pathway, phage genomes are 
replicated and packaged into new phage particles, which are released by lysis of the 
bacterial cell (Hatfull, 2011). During lysogenic growth, the phage genome is integrated into 
the host genome via a phage-encoded protein called the integrase (Hatfull, 2011). The 
integrated phage genome is called a prophage and it is replicated each time the bacterial 
cell replicates (Hatfull, 2011).  
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Understanding the organization of cluster G genomes allows for further 
understanding of their lysogenic regulation. The genomes of cluster G mycobacteriophage 
are relatively small at around 40 kbp and organized into a left arm of rightward-transcribed 
genes and a right arm of leftward and rightward transcribed genes (Figure 1) (Sampon et 
al., 2009). The left arm contains genes involved in particle structure and assembly, 
including one operon which encodes the structural genes, terminase, portal protein, capsid 
maturation protease, and gp5 (Sampson et al., 2009). gp5 is a small gene of unknown 
function, but has strong HHpred matches to the ribosome modulation factor of Escherichia 
coli (Zimmermann et al., 2018). The right arm encodes genes that are predicted to be 
involved in the early lytic cycle, but the majority of genes have no known function 
(Sampson et al., 2009). Some cluster G genomes, including BPs, contain a Mycobacterium 
phage mobile element (MPME) in their right arm (Sampson et al., 2009). The function of 
the gene within the MPME (gp58 in the BPs genome) is not known, but presumed to be a 
transposase (Sampson et a., 2009).  The left and right arm are separated by an integration 
cassette, which encodes an integrase gene and transcriptional regulators, the immunity 
repressor and Cro-like protein, that regulate genes involved in lytic versus lysogenic 
growth (Sampson et al., 2009).  
Phage use various mechanisms to establish and maintain lysogeny, including 
proteins expressed from an integration cassette. Temperate phage that do not have an 
integration cassette utilize a plasmid-like partitioning system that allows them to partition 
episomal phage genomes into dividing cells (Dedrick et al., 2016). Most temperate phage 
maintain lysogeny by integrating the phage genome into that of the host (Hatfull, 2011). 
This requires a phage-encoded integrase cassette that includes an integrase and an 
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immunity repressor protein that represses lytic gene expression (Hatfull, et al., 2011). 
During lysogeny, the bacterial cell containing the phage genome is termed a lysogen, while 
the integrated phage genome is termed a prophage (Hatfull, 2011). In the Cluster G phage, 
the integrase and repressor establish lysogeny in an integration-dependent manner 
(Sampson et al., 2009).  
 
Phage Integrases   
Phage integrases utilize a site-specific mechanism to mediate integration into the 
host cell (Groth et al., 2004). Recombination occurs via a tyrosine or serine integrase, 
which initiate attack of the DNA sugar-phosphate backbone at two sites of recombination 
in the phage genome, called the phage attachment site (attP), and the bacterial attachment 
site (attB) in the bacterial genome (Groth et al., 2004). Most phage utilize a tyrosine 
integrase, which recognize larger core attachment sites, 30 – 40 bp in length, with an 
inverted recognition sequence region (Groth et al., 2004). Recombination occurs when a 
nucleophilic tyrosine nicks one strand of each att site, resulting in the formation of a 
Holliday junction (Holliday, 1964, Grindley et al., 2006). The Holliday junction eventually 
 
Figure 1. Genome map of BPs drawn to scale with the ruler indicating the coordinates of the genome in 
units of kilobasepairs (Kbp) (Cresawn et al., 2011). Genes transcribed rightwards are positioned above the 
ruler and genes transcribed leftwards are positioned below the ruler. Genes are color coded based on 
similarity with other genes in the Phamerator database.  
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resolves and the resulting attL (left) and attR (right) sites are hybrid sequences of the attP 
and attB sites, leaving the prophage sequence flanked by the attL and attR sites (Groth et 
al., 2004). The new prophage state is maintained via expression of the prophage-encoded 
repressor (Petrova, 2015). 
Phage Repressors  
The most highly expressed gene during lysogenic infection is typically the repressor 
and its function is to prevent lytic genes from being transcribed to maintain the lysogenic 
state (Petrova, 2015). The most well-studied repressor system is that of the temperate E. 
coli phage, Lambda (ƛ) (Gao et al., 2013). The ƛ immunity cassette contains genes that 
encode transcriptional regulators CI, CII, and Cro (Figure 2). CI and CII expression 
promotes lysogenic growth and Cro expression promotes lytic growth (Atsumi, 2006). CI 
and Cro are divergently transcribed and there are three operator sequences that overlap the 
promoters for these genes (Atsumi, 2006). From right to left the operator sites are termed 
OR3, OR2 and OR1. The CI protein acts as a repressor for lytic genes by binding to OR1 and 
OR2 upstream of the promoter PR, thus prohibiting the polymerase from binding the 
rightward promoter and transcribing lytic genes, including Cro (Atsumi, 2006). Cro will 
bind to OR3 and OR2 upstream of the leftward promoter PRM. Binding of Cro prevents 
transcription of CI, while allowing transcription from PR and expression of lytic genes 
(Atsumi, 2006).  
The lytic/lysogenic decision is dependent upon levels of the CII transcriptional 
activator that promotes transcription of integrase (from PI) and of CI from the repressor 
establishment promoter (PRE) (Rokney et al., 2008). The stability of the CII protein 
determines its ability to stimulate transcription of those genes (Rokney et al., 2008). When 
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the nutrient status of the cell is high, HflA protease complex levels are high, and CII is 
degraded by the HflA protease complex. This allows accumulation of Cro in the cells, 
transcription from PR, and the cells will undergo the lytic cycle (Rokney et al., 2008). When 
nutrient levels in the cell are low, HflA protease complex levels are low, and CII is not 
degraded by the HflA protease complex, allowing establishment of CI in the cells. This 
allows continued transcription from PRM, and the phage undergoes the lysogenic growth 
cycle (Figure 2) (Rokney et al., 2008). Phage repressors, such as CI, can also bind to the 
genomes of similar superinfecting phage and prohibit lytic gene expression, thus conferring 
superinfection immunity (Sampson et al., 2009). Although the Lambda model is the most 
well-studied, CI/Cro systems have been found in many prophage, including those 
belonging to Cluster N and Cluster G (Dedrick et al., 2017., Broussard et al., 2013).  
 
 
BPs Maintenance of Lysogeny 
BPs is a temperate, Cluster G phage (Sampson et al., 2009). It has a broad host 
range capable of infecting M. smegmatis, M. abscessus, M. chelonae, and M. tuberculosis 
(Illingworth, unpublished, Jacobs-Sera et al., 2012, Dedrick et al., 2019 (B)). BPs infects 
M. smegmatis with an efficiency of lysogeny of 5% and M. chelonae WT with an efficiency 
of lysogeny of 25% (Jacobs-Sera et al., 2012, Molloy, unpublished). BPs can infect M. 
tuberculosis with a reduced efficiency of lysogeny when there is a single amino acid 
 
PRM PR
OR3 OR2 OR1
Lysogenic
C1 cro
Lytic gene	
transcription
PRE
genetranscription
Figure 2. Model of Lambda 
repressor expression. Upon 
integration, dimers of the 
lysogenic repressor protein, CI 
(light purple), will bind to OR1 and 
OR2, prohibiting transcription of 
the lytic repressor, Cro, from the 
lytic promoter, PR. The RNA 
polymerase is recruited to the 
lysogenic promoter, PRM, and CI is 
continuously expressed.  
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substitution in one of its tail fibers (Jacobs-Sera et al., 2012). Upon infection, the BPs 
genome integrates into the host genome where it is maintained as a prophage (Broussard 
et al., 2013). The BPs repressor functions only upon integration of the BPs genome into 
that of its bacterial host (Broussard et al., 2013).  
Bps Integration Cassette and Integration-Dependent Immunity 
BPs encodes an unusual integrase and immunity cassette in that the attP site is 
located within the 3′ end of the repressor (Broussard et al., 2013). The linear BPs genome 
is separated by an integration cassette that encodes a tyrosine integrase, a leftward-oriented 
immunity repressor (gp33) a rightward transcribed Cro (gp34), and an attP located within 
the 3′ end of the repressor (Figure 3). Upon integration at the attP site, the repressor is 
truncated (Broussard et al., 2013). Truncation of the repressor gene results in synthesis of 
a repressor protein that lacks the C-terminus, which includes ssrA-like tag (Broussard et 
al., 2013). This sequence is recognized and targets the protein for degradation by ClpXP 
or ClpAP proteases (Broussard et al., 2013). Removal of the 3′ end of the repressor gene 
upon integration therefore allows expression of a stable repressor protein that will repress 
transcription of lytic genes and promote the lysogenic lifestyle in a manner similar to phage 
ƛ (Broussard et al., 2013).  
The main role of gp33 is to repress the expression from lytic gene promoters, 
including promoter PR. The binding sites (called operators) for the active repressor consist 
of a 12-bp palindrome sequence of 5′-CGACATATGTCG-3′ (Villanueva, 2015). The 
operator upstream of PR is termed OR, while the operator upstream of the lysogenic promoter 
PRep is termed ORep. The active repressor gp33103 (truncated prophage version) will bind to the 
operator site OR, thus prohibiting RNA polymerase from binding and transcribing lytic 
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genes, including Cro (Villanueva, 2015). Expression of the repressor from the promoter 
PRep maintains the prophage in the lysogen, while conferring superinfection immunity to the 
host. Now that the prophage is integrated into the lysogen, its survival is dependent on that 
of its host. Many prophage have evolved to contribute to host fitness and pathogenesis 
(Brussow et al., 2004).  
Role of Prophage in Mycobacterial Disease 
Almost all pathogenic bacteria carry prophage in their genomes and prophage are 
known to impact host fitness in a variety of ways (Brussow et al., 2004). Prophage 
rearrangements can be beneficial for the host, they can disrupt host genes, protect their host 
from lytic infection by similar phage (superinfection immunity) and they can introduce 
genes that increase the virulence of the host (Brussow et al., 2004). Some prophage do so 
by encoding obvious virulence factors. In the example of Stx-producing Escherichia coli 
(STEC), a Shiga-like toxin is encoded by the prophage and E. coli only produces illness 
when the Shiga-like toxin is present (Fang et al., 2017). Both Corynebacterium diphtheriae 
and Clostridium botulinum are also infected with phage that encode toxin factors (Wang, 
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Figure 3. BPs integration cassette. The lysogenic promoter, PRep, and lytic promoter, PR, are indicated 
by black arrows, showing the direction of transcription of the immunity repressor (gp33) and Cro-like 
protein (gp34), respectively. The phage attachment site (attP) is located with the BPs repressor gene, 
gp33. Cloning inserts BPsIR and BPsIattP were amplified from the BPs genome are indicated below the 
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(gp32). Insert BPsIattP encodes the integrase (gp32), attP site, and 221-bp upstream of the attP site. 
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2010). However, not all prophage encode obvious virulence factors. This is the case for the 
phiRv1 and phiRv2 prophage of M. tuberculosis. For example, most strains of the M. 
tuberculosis complex (MTBC) carry the prophage phiRv1or phiRv2 (Fan et al., 2016). The 
prophage genes were upregulated in a nutrient starvation model of M. tuberculosis in the 
presence of oxidative phosphorylation inhibitors (ie: Valinomycin), and in the presence of 
metabolism inhibitors (ie: hypoxic conditions) (Fan et al., 2016). While the most virulent 
strain M. tuberculosis H37Rv carries both, the non-virulent strain M. bovis (BCG) does not 
carry phiRv1 nor phiRv2. This leads to the hypothesis that prophage are responding to 
changes in their host’s environment and somehow impacting host virulence.  
The presence of the prophage BPs alters expression of 7.7% of the bacterial genes 
associated with virulence and antibiotic resistance in M. tuberculosis (Molloy, 
unpublished, Burian et al., 2012). One gene that is significantly upregulated in the BPs-M. 
chelonae lysogen is the transcription factor whiB7, which regulates transcription of genes 
involved in antibiotic resistance (Burian et al., 2012, Burian, 2018). Since many genes 
involved in antibiotic resistance belong to the WhiB7 regulon, increased levels of whiB7 
expression should lead to increased levels of antibiotic resistance. Compared to M. 
chelonae WT, BPs-M. chelonae lysogens are more resistant to aminoglycosides 
(kanamycin and amikacin) and tetracycline, antibiotics commonly used to treat M. 
abscessus and M. tuberculosis infections (Molloy, unpublished). The second most 
downregulated gene in the lysogen is a padR-like gene that may also be involved in 
antibiotic resistance. The first PadR transcription factor described in bacteria is a negative 
controller of phenolic acid decarboxylase, which detoxifies harmful phenolic acids (Park 
et al., 2017). In other bacterial species, PadR-like transcriptional regulators control 
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expression of stress response genes including multidrug efflux pumps, and transmembrane 
proteins that respond to stressors on the cell envelope (Hauf et al., 2019, Fibriansah et al., 
2012, Vatlin et al., 2018). PadR family of transcriptional regulators are typically 
downregulated in the presence of environmental stressors, such as antibiotics, allowing de-
repression of genes needed to survive the environmental stress (Park et al., 2017). The 
presence of a prophage in the mycobacterial host, M. chelonae, alters antibiotic resistance 
and expression of genes known to influence antibiotic resistance. How the presence of the 
prophage alters gene expression and antibiotic resistance is not understood.  
It is possible that prophage gene products are driving changes in mycobacterial host 
gene expression. The most highly expressed gene in the BPs genome during lysogeny is 
the immunity repressor, gp33 (Figure 4) (Molloy, unpublished). The role of the immunity 
repressors, including gp33, is to bind operator sequences in the phage genome and regulate 
transcription (Villanueva, 2015). If gp33 also binds to sequences in the M. chelonae 
genome that are similar to the gp33 operator sequence, gp33 could be regulating 
transcription of M. chelonae genes. There are eight sequences in the M. chelonae genome 
that resemble the consensus operator sequence for gp33 (5′-CGACATATGTCG-3′), three 
of which are upstream of a padR-like gene, the second most downregulated gene in the 
BPs-M. chelonae lysogen RNAseq data set (Hutchison, personal communication). It is 
unknown if gp33 is binding to these operator sites or is responsible for the changes in 
whiB7 and padR expression and antibiotic resistance in the BPs-M. chelonae lysogen.  
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MATERIALS & METHODS 
 
 
 
Bacterial Strains and Growth Conditions 
Mycobacteria were grown in liquid 7H9 media supplemented with 10% oleic acid-
albumin-dextrose (OAD) (Difco, Franklin Lakes, NJ), 1 mM CaCl2, and 0.05% Tween 80 
with shaking at 250 rpm or on Difco 7H10 agar supplemented with OAD. M. chelonae 
Bergey (ATCC: 19535; NZ_CP010946.1) and M. smegmatis mc2155 (ATCC: 700084; 
NC_008596.1) cultures were grown at 30°C and 37°C, respectively. Escherichia coli 5-
alpha (New England Biolabs (NEB), Ipswich, MA) cultures were grown in liquid Luria 
broth (Difco, Franklin Lakes, NJ) at 37°C with shaking at 250 rpm or on Luria agar 
supplemented with 50 µg mL-1 kanamycin (Difco).  
Plasmid Construction 
Plasmid pMH94 provided the backbone for pMHIR and pMHIattP and has 
previously been described (Lee et al., 1991). The plasmid pMH94 was digested with the 
restriction endonuclease SalI, according to manufacturer’s instructions (NEB, Ipswich, 
MA), to remove a 2,083-bp fragment containing the L5 integrase and L5 attP site 
(coordinates 906 – 2,989 of the pMH94 plasmid). Gel electrophoresis was performed to 
determine pMH94 had been successfully digested with SalI via the presence of 2,083-bp 
and 4,136-bp fragments. The 4,136-bp fragment, lacking the L5 integration cassette, was 
captured via a Lonza FlashGelTM Recovery Cassette according to manufacturer's 
instructions (Lonza, Basel, Switzerland). Primers were designed using Primer3 
(Untergasser et al., 2012) to amplify target regions of the BPs genome (Table 1). Plasmids 
pMHIR and pMHIattP were constructed as described by Sampson et al (2009). Fragment 
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BPsIR (BPs Integrase Repressor) includes the BPs integrase (gp32), immunity repressor 
(gp33), attP site within gp33, and intergenic region between gp33 and gp34 (Figure 3). 
Fragment BPsIattP includes the BPs integrase (gp32), the attP site within gp33, and 221-
bp upstream of the attP site (Figure 3). The BPsIattP fragment does not include the entire 
repressor gene sequence (gp33) and therefore served  as a control for the BPsIR sequence.  
A second PCR reaction was performed using 60-mer primers that are specific to 
30-bp of the flanking region of each insert and to 30-bp of the ends produced by SalI 
digestion of the pMH94 plasmid. Gibson Assembly cloning reactions containing the SalI-
digested pMH94 plasmid and the control and experimental PCR products, BPsIattP and 
BPsIR, respectively, were performed in reaction ratios of insert to plasmid of 2:1 and 3:1 
according to the manufacturer’s recommendations (NEB) (Figure 5). Cloning products 
were transformed into competent E. coli cells (NEB) and plated onto Luria agar plates 
containing 50 µg mL-1 of kanamycin to select for cells with integrated plasmids. Plates 
were incubated at 37 °C overnight. Transformed colonies were grown overnight at 37 °C 
in 5 mL of Luria broth (Miller) containing 50 µg mL-1 of kanamycin. Plasmid DNA was 
isolated via the Wizard Plus SV MiniPrep DNA Purification System (Promega, Madison, 
WI) according to the manufacturer’s instructions. DNA sequencing was performed to 
confirm cloning of correct sequences.   
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Table 1. PCR primer sequences. 
Primer name Primer sequence Amplicon 
size 
Coordinates 
 
gp32attP+221_ forward  
 
5’-
CGCTGCCAGACCCCAATTGCGG
AAC-3’ 
  
  1,575 29,135 – 
27,722 
gp32attP+221_ reverse 5’-
CTACTGATCGCGCGCCTTGAAG
CTG-3’ 
  
  1,827  
gp32attPgp33IG_reverse 5’-
CGGTTGGGGTCATGTGCACCAA
CATAG-3’ 
  
   906 –2,480 
pMH9432attP+221_ reverse 5’-
CCCGGCCAAGCTTGCATGCCTG
CAGGTCGACTACTGATCGCGCG
CCTT-3’ 
  
  1,635  
 
pMH94gp32attPgp33IG_ 
forward  
 
5’-
CGAGCTCGGTACCCGGGGATCC
TCTAGAGCGCTGCCAGACCCCA
ATTGCGGAAC-3’ 
  
  1, 887 906 –2,731 
pMH94gp32attPgp33IG_ 
reverse 
5’-
CGGCCAAGCTTGCATGCCTGCA
GGTCGACGGTTGGGGTCATGTG
CACCAACATAG-3’ 
  
    
BPs_attP_left 5’-
GCTTTATCCAGGGTTGACCA-
3’ 
  
  203  
BPs_attP_right 5’-
GTTCCGATTATTGGCTGGA-3’ 
  
  514  
BPs_attB_left 5’-
GTCTCGTTACTGGCGAGCTT-
3’ 
  
  548  
BPs_attB_right 5’-
CGGGTAGTAGGCAGATGAGC-
3’ 
  
  238  
BPs_attB_left    
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Agarose Gel Electrophoresis 
PCR products were separated on a 2% SeaKemⓇ LE Agarose gel in 1X TAE buffer 
(40 mM Tris-acetate, 20 mM acetic acid, 2 mM Ethylenediaminetetraacetic acid). Gels 
were stained with SYBRTM Safe DNA Gel Stain and visualized on the Azure Biosystems 
C200 Imaging System. 
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Figure 5. Gibson Assembly 
Cloning of insert BPsIR into 
SalI-digested pMH94 plasmid 
vector, adapted from Gibson 
et al. (2009). Primers were 
designed to amplify a 1,826-
bp fragment from the BPs 
genome (29,521 – 27,696) 
called BPsIR and a 1,575-bp 
control insert (29,270 – 27, 
696) called BPsIattP. 
Fragments were amplified via 
PCR and inserted into a 
plasmid vector via Gibson 
Assembling Cloning to create 
pMHIR and pMHIattP, 
respectively. 
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Electroporation of M. chelonae Cells 
Electrocompetent M. chelonae cells were prepared by washing log-phase M. 
chelonae cells in ice-cold 10% glycerol according to De Moura et al (2012). Plasmid DNA 
in concentrations of 100, 300, and 500 ng was electroporated into 100 µL of 
electrocompetent M. chelonae with a single pulse (2.5 kV, 25 mF, and 1,000 Ω). Cells were 
allowed to recover in 900 µL of 7H9-OAD at 30 °C for 4 h before plating onto 7H10 agar 
containing 250 µg mL-1 of kanamycin. Plates were incubated at 30 ℃ for 5–6 d. Primer 
pairs were designed to detect the BPs attL and attR sites, and the L5 attL and attR sites to 
verify integration of pMHIattP and pMHIR plasmids and the control plasmid (undigested 
pMH94), respectively, into the M. chelonae genome (Figure 6). Transformants were picked 
and PCR screened for the presence of attL and attR sequences.  
 
 
 
 
42	kb
BPs
M.	chelonae
repressor
integrase
BPs	
prophage
attL
514-bp
attP
203-bp
attB
548-bp
integraserepressor
1 2
3 4
4 1 2 3attR238-bp
Figure 6. Model of BPs genome 
integration into the bacterial genome. 
Integration is catalyzed by the phage 
integrase acting on identical 
sequences, attP and attB, on the 
phage and bacterial genomes, 
respectively. Upon integration, the 
attL and attR sites are present in the 
lysogen. Integration of the plasmids 
pMHIR and pMHIattP occurs in the 
same manner. To detect integration 
of the BPs genome or plasmids 
pMHIR and pMHIattP, primers were 
designed to bind to sequences 
flanking the BPs attP (primers 1 and 
2) and attB sites (primers 3 and 4. 
Upon integration, primers 1 and 4 
will amplify the attL site, while 
primers 2 and 3 will amplify the attR 
site. 
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Immunity Assays 
Cultures were grown to an optical density (OD600) of  ≥ 5 and plated in 4.5 ml of 
7H9 top agar onto L agar plates. Serial 10–fold dilutions of BPs lysate were applied in 5-
µL quantities onto lawns of M. chelonae WT, M. chelonae (pMHIR) and M. chelonae 
(pMHIattP). Plates were incubated at 30 °C for 48 h and screened for plaques.  
RNA Isolations and qRT-PCR Assays 
Cultures of M. chelonae were grown to an OD600 of 0.8 or 1.0. Cells were harvested 
in a quantity of 4 mL, in replicates of 8, into 8 ml of RNAprotect Bacteria reagent (Qiagen, 
Hilden, Germany) and incubated for 5 min at RT. Cells were centrifuged at 5,000 x g for 
10 min. Supernatant was removed and the cell pellets were resuspended in 100 µL of TE 
containing 20 mg mL of lysozyme (Sigma Aldrich, St. Louis, MO). After incubating for 
40 min at RT, 700 µL of RLT buffer containing β-mercaptoethanol was added to cell 
suspensions (Qiagen). Cells were lysed in 2-mL Lysing Matrix B tubes (MP Biomedicals) 
and homogenized for 8 min at 50 Hz in the Qiagen TissueLyser LT using an ice-cold tube 
adapter. Total RNA was isolated from lysates using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s recommendations. To remove genomic DNA, samples 
were treated with DNAseI (Qiagen) on the column according to the manufacturer's 
recommendations. To ensure that all genomic DNA was removed from RNA samples, a 
second DNase treatment (Turbo DNase, Life Technologies) was conducted after elution 
from RNeasy Mini Kit columns. The quantity and quality of RNA was determined via 
analysis with Nanodrop One spectrophotometer (Thermo Fisher Scientific) and FlashGelTM 
RNA system (Lonza).  
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cDNA was synthesized from 500 ng of RNA in 20-µL reaction volumes using the 
Quantabio qScript Synthesis kit, according to the manufacturer’s instructions (Quantabio, 
Beverly, MA). Samples were diluted 1:6 in 10 mM Tris-HCl and cDNA was used to 
conduct quantitative real-time PCR assays to analyze gene expression levels. Template 
cDNA was added in volumes of 1 µL (0.02 ng µL-1) to triplicate 25-µL qRT-PCR reactions 
containing 1x Perfecta qPCR Supermix (Quantabio), 200nM of each gene-specific primer. 
Reactions were run under the following program in the Bio-Rad CFX96 Real-Time system 
(Bio-Rad Laboratories, Hercules, CA): 95 °C for 3 min followed by 40 cycles of 95 °C for 
10 s, 60 °C for 30 s and 65 °C for 5 s, and 65 °C for 5 s. Gene expression was measured 
with SYBR Green and reported expression levels are indicative of 2-∆∆Ct (Livak, KJ., 
2001). Significant differences in expression were determined by ANOVAs conducted with 
JMP statistical discovery software and significance was indicated by P < 0.05 (Jones, B., 
Sall, J., 2011).  
MIC Assays 
To analyze the impact of gp33 on M. chelonae antibiotic resistance, minimum 
inhibitory concentration (MIC) assays were conducted. M. chelonae WT, BPs lysogen, and 
recombinant strain cultures were grown overnight to an OD600 of 0.1–0.3 in 7H9-OAD + 
0.05% Tween 80 media (Middlebrook). Cultures were diluted to an OD600 of 0.005 and 
incubated at 30 °C with shaking for 4 h before applying cells in 50-µL quantities to 96 well 
plates containing 50 µL of 7H9 media with varying concentrations of antibiotics. 
Tetracycline and clarithromycin assays were performed using two-fold serial dilutions of 
the antibiotics (0.5 – 64 and 0.19 – 25 µg mL-1, respectively). Clarithromycin was prepared 
in DMSO, therefore an equivalent amount of DMSO was included in all wells. Each strain 
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was tested at each antibiotic concentration in replicates of six and no-antibiotic controls 
and no bacteria controls were performed in replicates of 16. Inoculated plates were sealed 
with sterile porous seals (VWR), wrapped in Parafilm (Bemis, Neenah, WI) and incubated 
at 30 °C for 2 d before adding 1 µL of AlamarBlue (BioRad, Hercules, CA). After 
incubation at 30 °C for 1 d, the optical density (OD) was measured at 570- and 600 nm and 
the percent viability of cells was calculated as the percent difference between antibiotic-
treated cells and untreated cells according to the manufacturer’s instructions. Each assay 
was replicated in three independent experiments. 
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RESULTS  
 
 
 
Gene Expression Profile of the BPs Prophage in M. chelonae WT 
 To determine which genes are expressed from the BPs prophage genome during 
lysogenic infection of M. chelonae, RNA was isolated from BPs-M. chelonae lysogens and 
submitted for RNAseq analysis. RNAseq reads were aligned to the BPs genome (Figure 
4). The two most highly expressed genes of the BPs genome were the immunity repressor, 
gp33, and a gene of unknown function within the mycobacterial phage mobile element 
(MPME), gp58. There were also low levels of reads mapped to BPs gp5 and gp23–36.  
Construction of BPs gp33 Expression Plasmids, pMHIR and pMHIattP 
The recombinant strain M. chelonae (pMHIR) that expresses the BPs immunity 
repressor and the control strain M. chelonae (pMHIattP) were created to test the effect of 
the BPs repressor on bacterial gene expression and antibiotic resistance. Plasmids pMHIR 
and pMHIattP were constructed using plasmid pMH94 and the amplified fragments (Figure 
5 and Figure 7) (Lee et al., 1991). This plasmid contains a kanamycin resistance gene but 
lacks a mycobacterial origin of replication and therefore cannot be maintained in a bacterial 
cell unless it has integrated into the bacterial genome via a plasmid-encoded integrase 
cassette. The 2,083-bp L5 integrase cassette was removed by digesting pMH94 with SalI 
endonuclease and replaced with the BPs integration cassette. Two variations of BPs 
integration cassette inserts were PCR amplified from the BPs genome. The first insert, 
BPsIR, includes sequences for the BPs integrase (gp32), attP site, immunity repressor 
(gp33), and Prep (promoter for gp33) (Figure 3).  The control insert, BPsIattP, encodes the 
integrase, attP site, and 221-bp upstream of the attP site (Figure 3). The PCR products were 
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cloned into SalI-digested pMH94 using Gibson cloning resulting in plasmids pMHIR and 
pMHIattP (Figure 7). Plasmid insert sequences were confirmed by sequencing.  
 
After electroporation of plasmids into M. chelonae, recombinant strains were 
validated via PCR and agarose gel electrophoresis using primers specific to BPs sequences 
flanking the phage attachment site, attP (primers 1 and 2) and sequences flanking the 
bacterial attachment site, attB (primers 3 and 4). Upon successful integration, primers 1 
and 4 produced a 514-bp product and 2 and 3 produced a 238-bp product, which were 
consistent with the size of PCR amplification from the integration attachment sites attL 
and attR, respectively (Figure 8).   
  
 
 
L5	integrase	cassetteSalI SalIpMH94 6,219	bp
KanR
BPs	integrase	cassette
pMHIR 5,963	bp
KanR
pMHIattP
2,083	bp
gp33gp32
attP
BPs	integrase	cassette
5,712	bp
KanR
gp33gp32
attP
Figure 7. Experimental design of integrative plasmids pMHIR and pMHIattP encoding BPs integrase 
cassette as described by Sampson et al. pMHIR encodes the integrase gene (gp32), the phage attachment 
site attP, the immunity repressor (gp33), and the intergenic region between gp33 and gp34 that includes 
the gp33 promoter (indicated by black arrow). pMHIattP encodes the integrase gene (gp32), the attP site, 
and an additional 221-bp upstream of the attP site. pMHIattP is missing the promoter and 5´end of the 
gp33 gene. 
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To determine if a functional gp33 immunity repressor is produced from the integrated 
plasmid pMHIR, superinfection immunity assays were performed on M. chelonae 
(pMHIR) and control strain M. chelonae (pMHIattP) (Figure 9). M. chelonae (pMHIR) 
was immune to infection by BPs, indicating expression of a functional repressor, whereas, 
M. chelonae (pMHIattP) was susceptible to infection by BPs.  
 
650
500
400
300
200
BPs_attL
BPs_attR
L5_attL
L5_attR
BPs_attB
Figure 8. Agarose gel electrophoresis of PCR diagnostic products indicating phage attachment sites, attL 
and attR, detected in recombinant and lysogen strains of M. chelonae. Attachment sites, attL and attR, 
were detected in DNA isolated from BPs-M. chelonae lysogen (lane 3), and recombinant M. chelonae 
carrying plasmids pMHIR (lane 6) and pMHIattP (lane 5). As a control, PCR was also performed on M. 
chelonae WT DNA (lane 2) to amplify the bacterial attB site and M. chelonae (pMH94) (lane 4) was used 
as an integration control for the recombinant strains. M. chelonae (pMH94) carries the L5 integration 
cassette with the L5 attL and L5 attR. Lanes 1 and 7 contain the molecular size markers. Expected product 
sizes: BPs attB – 548 bp (Lane 2), BPsattL – 514 bp (Lane 3, 5, 6), BPsattR – 238 bp (Lane 3, 5, 6), 
L5attL – 623 bp (Lane 4), L5attR – 385 bp (Lane 4). 
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Figure 9. To determine if the recombinant plasmid pMHIR produces functional immunity repressor in M. 
chelonae, a superinfection immunity assay was performed. Serially diluted BPs lysate was applied to 
lawns of M. chelonae (pMHIR) and M. chelonae (pMHIattP). 
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Gp33 Transcription Levels are Comparable Between Recombinant Strains and  
BPs-M. chelonae Lysogens 
To confirm expression of gp33 from recombinant strains, qRT-PCR was performed 
on RNA isolated from M. chelonae (pMHIR) and M. chelonae (pMHIattP). In cells grown 
to optical densities of 0.8, gp33 expression was 4-fold lower in the recombinant strain M. 
chelonae (pMHIR) than the BPs-M. chelonae lysogen strain (Figure 10A). Expression of 
gp33 was comparable to that of the BPs-M. chelonae lysogens in cells grown to optical 
densities of 1.0 (Figure 10B).  
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Gp33 has Minimal Impact on the Expression of M. chelonae Genes whiB7 and padR 
To determine if gp33 is responsible for the induction of whiB7, qRT-PCR assays 
were performed on RNA isolated from M. chelonae WT, BPs-lysogens and the 
recombinant strains. whiB7 expression was 50-fold greater in the BPs-M. chelonae lysogen 
relative to M. chelonae WT strain. whiB7 was not elevated in the recombinant strain 
relative to the M. chelonae WT control strain. At cell densities of 0.8, whiB7 expression in 
M. chelonae carrying pMHIattP and pMHIR was nearly equivalent to that of M. chelonae 
WT with fold changes of 1.5 and 1.1, respectively (Figure 11A). At cell densities of 1.0, 
expression of whiB7 was increased in the recombinant strains but was not significantly 
upregulated in the M. chelonae (pMHIR) strain compared to the M. chelonae (pMHIattP) 
strain with fold changes of 3.5 and 2, respectively (Figure 11B).  
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Due to possible vector-specific effects, it is difficult to determine the impact of 
gp33 on padR expression. There was no significant difference in padR expression in the 
pMHIR strain relative to the plasmid control strain at cell densities of 0.8.  padR expression 
was decreased by 2-fold in both recombinant strains compared to M. chelonae WT and the 
difference between the two plasmid strains was not significant (Figure 12A). In cells grown 
to a higher density of 1.0, the vector appeared to have an inducing effect as both 
recombinant strains express padR at levels 5–6-fold higher than M. chelonae WT, and there 
was no significant difference between the recombinant strains (Figure 12B).  
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The Effect of gp33 Expression on M. chelonae Antibiotic Resistance 
To measure the effect of gp33 expression on the antibiotic resistance of M. 
chelonae, MIC assays were performed on recombinant strains and compared to M. 
chelonae WT and BPs-M. chelonae lysogen strains. Expression of gp33 did not appear to 
alter antibiotic resistance. There was no significant difference in resistance to tetracycline 
between the two recombinant strains relative to M. chelonae WT (Figure 13A). M. 
chelonae (pMHIattP) treated with acivicin, an inducer of whiB7 expression, did not show 
overall increased resistance to tetracycline compared to M. chelonae (pMHIR) and M. 
chelonae (pMHIattP). These results are not comparable to the BPs-M. chelonae lysogen, 
which shows increased resistance at increasing concentrations of tetracycline. In the 
presence of clarithromycin, M. chelonae (pMHIR) did show increased resistance at 
concentrations of 0.20-25 µg mL-1 compared to M. chelonae (pMHIattP) and M. chelonae 
(pMHIattP) plus acivicin (Figure 13B).  However, a dose-dependent response was not seen 
and therefore this assay needs to be repeated before a conclusion about the impact of gp33 
on resistance to clarithromycin can be made.  
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The Effects of Co-Expression of BPs gp5 and the Immunity Repressor gp33 on  
M. chelonae Gene Expression 
Because gp33 expression was lower than that of the BPs-M. chelonae lysogen when 
grown to densities of 0.8, and because gp33 expression alone did not appear to impact 
whiB7 nor padR expression, we were curious if the co-expression of gp5 and gp33 would 
increase expression of gp33 and possibly drive changes in padR. A plasmid encoding BPs 
gp5 was constructed from plasmid pMO01 (Dedrick et al., 2016), which has a constitutive 
M. bovis Heat Shock Protein (hsp) promoter and is maintained by a parABS partitioning 
system from mycobacteriophage RedRock (Dedrick et al., 2016). If gp5 affects expression 
of gp33, we expect to see higher gp33 expression levels from M. chelonae (pMHIR) in the 
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presence of gp5 relative to M. chelonae (pMHIR) strains with the empty pMO01 vector. 
To verify the presence of the plasmids, recombinant strains were analyzed by PCR during 
the culture process prior to RNA isolations. The plasmids were lost during subculturing 
just prior to RNA isolations, yet we still saw differential gene expression (PCR data not 
shown). Levels of gp33 transcript were nearly 2-fold higher in M. chelonae carrying 
pMHIR and gp5 relative to strains carrying pMHIR and empty pMO01 vector, although 
the difference was not statistically significant (Figure 14). padR expression was not 
significantly down-regulated in the M. chelonae recombinant strain carrying pMHIR and 
gp5 when compared to M. chelonae carrying pMHIR and empty vector pMO01 (Figure 
15). padR expression levels in M. chelonae carrying pMHIR and empty vector and M. 
chelonae carrying pMHIR and gp5 were decreased by 0.7- and 0.8-fold, respectively, 
indicating that the presence of the pMO01 plasmid may have a slight suppressive effect.  
 
Figure 14. Average relative expression of BPs gp33 in cells grown to an optical density of 1.0 as measured 
with SYBR Green quantitative RT-PCR (F = 18.07, P = 0.0029). Graphs are indicative of averages +/- the 
standard errors of the mean, n = 3. Letters indicate which strains are statistically different.  
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Figure 15. Average relative expression of BPs padR in cells grown to an optical density of 1.0 as measured 
with SYBR Green quantitative RT-PCR. Graphs are indicative of averages +/- the standard errors of the 
mean, n = 3 (F = 10.49, P = 0.0038). Letters indicate which strains are statistically different. 
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DISCUSSION 
 
 
 
Mycobacteria, including M. abscessus and M. tuberculosis are becoming 
increasingly drug resistant and there is a need for alternative therapeutics (Lee et al., 2015). 
One mechanism of mycobacterial pathogenicity and antibiotic resistance that is not well 
understood is the role of prophage. Prophage (viruses that integrate their genomes into that 
of the host) likely increase the pathogenicity of mycobacterial hosts, but it is unknown how 
(Fan et al., 2016). Upon lysogenic infection, the prophage BPs causes significant 
differential expression of 7.74% of genes in the M. chelonae genome, including whiB7, a 
known regulator of antibiotic resistance genes, and padR, a gene associated with antibiotic 
resistance in other bacterial species (Burian et al., 2012, Park et al., 2017). The most highly 
upregulated BPs gene during lysogenic infection is the viral immunity repressor, gp33. Our 
hypothesis was that if the BPs immunity repressor (gp33) is responsible for the changes we 
see in the BPs-M. chelonae lysogen compared to M. chelonae WT, then a recombinant 
strain of M. chelonae expressing gp33 at levels comparable to that in the BPs lysogen 
should show similar gene expression and antibiotic resistance changes as the BPs-M. 
chelonae lysogen.  
The immunity repressor, gp33, is the most highly expressed gene in the BPs 
genome during lysogenic infection of M. chelonae and is the most logical candidate for 
altering mycobacterial gene expression (Figure 4). Phage immunity repressors are typically 
highly expressed during lysogeny (Dedrick et al., 2013., Dedrick et al., 2019). This is 
expected because high quantities of the immunity repressor are needed to repress lytic gene 
expression and maintain lysogeny (Petrova, 2015). Gp58 is also highly expressed, but 
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based on unpublished data from the Molloy lab, it likely does not play a role in whiB7 
expression. Gp58 is a novel Mycobacterium phage mobile element (MPME) found in some 
Cluster G phage (Sampson et al., 2009). There is no known function for gp58, but because 
it is the only ORF in the mobile element, it could be a recombinase and have DNA binding 
abilities. The Molloy lab has investigated whiB7 expression in M. chelonae carrying a 
prophage identical to BPs but lacks gp58 and whiB7 expression is elevated, suggesting 
gp58 is not playing a role in whiB7 expression (Molloy, personal communication). There 
are other genes expressed during BPS lysogeny at very low levels, including gp23-26, 
which are thought to be due to background lytic infection given their location within an 
operon of structural genes. There is always some background lytic gene expression within 
a lysogenic population (Nanda et al., 2015). We assumed the same for gp5, but given its 
predicted function as a ribosomal modulation factor, which can help stabilize 70S 
ribosomes to facilitate leaderless transcription, we sought to determine if co-expression of 
gp5 and gp33 increased gp33 levels, as gp33 is expressed as a leaderless transcript 
(Broussard et al., 2013). Overall, we chose to investigate further the immunity repressor, 
BPs gp33, given it is the most highly expressed gene and functions as a transcriptional 
regulator to alter gene expression.  
Gp33’s function as an immunity repressor and transcriptional regulator strengthens 
its candidacy for a regulator of bacterial gene expression. In the BPs phage, the gp33 
tetramer binds to palindromic operator sequences upstream and overlapping BPs lytic gene 
promoters with the conserved sequence 5′-CGACATATGTCG-3′ (Villanueva, 2015). 
Binding to these operator sites represses the transcription of these genes (Villanueva, 
2015). If there are sequences within the M. chelonae genome that overlap regulatory 
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sequences, it is possible that gp33 could be binding to and regulating transcription of 
bacterial genes. Eight such sequences were found in gene regulatory regions in the M. 
chelonae genome, three of which are located upstream of the second most downregulated 
gene in the BPs-M. chelonae RNAseq set, padR (Hutchison, personal communication). 
PadR-like transcription factors contain a winged helix-turn-helix domain in the N-terminal 
that interacts with palindromic operator DNA sequences (Park et al., 2017). The function 
of this PadR-like transcriptional regulator in M. chelonae is not known; however, in other 
bacterial species padR genes regulate genes involved in environmental stress responses 
(Park et al., 2017). This includes responses to phenolic acid, antibiotics, and other toxic 
compounds detected in the environment (Park et al., 2017). We do not know if padR in M. 
chelonae regulates antibiotic resistance genes, but given the increased antibiotic resistance 
of BPs-M. chelonae lysogens, it could be contributing to resistance. To show that padR is 
contributing to resistance, MIC assays would need to be run on an M. chelonae padR 
deletion strain and M. chelonae padR overexpression strain. To determine if gp33 drives 
changes in whiB7 and padR expression and antibiotic resistance in M. chelonae, a 
recombinant strain of M. chelonae that expresses gp33 in its active form was created.  
 A recombinant strain of M. chelonae (pMHIR) that expresses a functional 
immunity repressor was successfully created according to Sampson et al (2009). M. 
chelonae (pMHIR) carries pMHIR that has integrated into the BPs attB site and encodes 
the BPs integrase and immunity repressor (Figure 7). A plasmid control strain, M. chelonae 
(pMHIattP) was successfully created that encodes the integrase (gp32) and attP site but 
lacks an intact gp33 gene. The M. chelonae (pMHIR) strain demonstrates superinfection 
immunity, which indicates that gp33 expressed from pMHIR is functional and capable of 
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binding operator sequences and inhibiting transcription (Figure 9). qRT-PCR analyses 
indicate that the level of transcript expressed from pMHIR is comparable to that of BPs-
M. chelonae lysogens when RNA is harvested from cells at a density of 1.0 (Figure 10B). 
Given that a functional immunity repressor is present and transcript levels are comparable 
to that of the BPs-M. chelonae lysogen, changes in whiB7 and padR should be detected in 
M. chelonae (pMHIR) if gp33 is responsible for the gene expression changes in the 
lysogen. 
The BPs immunity repressor (gp33) does not appear to be responsible for whiB7 
induction. Based on qRT-PCR analyses, whiB7 expression is 8-fold to 50-fold higher in 
the BPs-M. chelonae lysogen than in M. chelonae WT in cells grown to an optical density 
of 0.8 and 1.0, respectively (Figure 11A and 11B). If gp33 were responsible for the changes 
we see in whiB7 expression, we would expect to see similar expression levels in M. 
chelonae (pMHIR) compared to the BPs-M. chelonae lysogen. whiB7 was not expressed 
in M. chelonae (pMHIR) at levels comparable to that of the BPs-M. chelonae lysogen at 
an optical density of 0.8 nor 1.0. whiB7 expression was not significantly higher in the 
recombinant strain M. chelonae (pMHIR) compared to the plasmid control strain M. 
chelonae (pMHIattP). Therefore, BPs gp33 is not likely responsible for the increase in 
whiB7 expression upon lysogenic infection of M. chelonae.   
  Gp33 also does not appear to be involved in padR downregulation. padR was the 
second most downregulated gene in M. chelonae according to RNAseq analysis. When 
qRT-PCR analyses were run on cells grown to an optical density of 0.8, padR was not 
significantly downregulated in the BPs-M. chelonae lysogen strain compared to the M. 
chelonae WT strain (Figure 12A). When cells are grown to an optical density of 1.0, the 
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same density used for RNAseq studies, padR expression decreases drastically and 
transcripts are hardly detectable in the BPs-M. chelonae lysogen compared to the M. 
chelonae WT strain, thus supporting RNAseq data (Figure 12B).  At an OD600 of 1.0, 
expression of gp33 leads to slightly downregulated padR levels relative to the control 
recombinant strain, but the difference is not significant (Figure 12B). Interestingly, padR 
expression is lower in both recombinant strains at an OD600 of 0.8 relative to the M. chelonae 
WT strain, suggesting that at densities of 0.8 the vector has a suppressive effect. But padR 
expression is higher in both recombinant strains relative to M. chelonae WT at an OD600 of 
1.0, suggesting the vector induces padR at densities of 1.0. If gp33 is responsible for the 
padR repression observed in the BPs-M. chelonae lysogen grown to a density of 1.0, we 
expect to see negligible levels of padR expression in the recombinant strain M. chelonae 
(pMHIR) grown to a density of 1.0. These data suggest that gp33 does not appear to be 
responsible for padR downregulation in the lysogen and downregulation of padR in the 
lysogen strain is density-dependent.  
While we do not know why there is a difference in padR expression at different 
densities, bacterial population density has been connected to gene expression regulation 
(Bassler, B., 1999, Bharati, B., Chatterji, D., 2013, Zhao et al., 2020). This is perhaps 
because as the cells enters late-log and stationary phase, resources for transcription are 
altered (e.g. sigma and anti-sigma factors) (Klumpp, S., Hwa, T., 2014, Flentie et al., 2016). 
The effects of the prophage or plasmids on padR expression would therefore be different 
depending on the transcription factors present in the cell at different densities (Park et al., 
2017). As an alternative explanation, many bacteria, including mycobacteria, can 
participate in quorum sensing. Quorum sensing occurs as changes in population density 
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triggers the release of molecules, which signal the release of secondary messengers. These 
messengers carry the signal to effector molecules that alter cellular functions, including 
expression of genes involved in antibiotic resistance (Bharati, B., Chatterji, D., 2013, Zhao 
et al., 2020). As the population of M. chelonae cells increases, signals could trigger 
downregulation of padR expression. Overall, given that the vector interfered with padR 
expression, further studies are required to fully rule out gp33 as an inhibitor of padR 
expression. 
 Gp33 does not appear to increase M. chelonae antibiotic resistance. This is 
unsurprising given that gp33 does not seem to alter transcription of genes involved in 
antibiotic resistance. MIC assays were performed with decreasing concentrations of 
tetracycline and clarithromycin, a drug typically used to treat M. abscessus infections. 
While M. chelonae (pMHIR) appears to show increased resistance to clarithromycin 
compared to M. chelonae (pMHIattP) and M. chelonae (pMHIattP) plus acivicin (a natural 
inducer of whiB7), a dose-dependent response is not seen (Figure 13B). We would expect 
to see little cell viability at a concentration of 25 µg mL-1 of clarithromycin and a steady 
increase in cell viability as the concentration decreases. Therefore, a conclusion from this 
data cannot be made. A dose-dependent response was seen in cultures grown in the 
presence of tetracycline. M. chelonae (pMHIR) did not show increased resistance to 
tetracycline compared to M. chelonae (pMHIattP) and M. chelonae (pMHIattP) plus 
acivicin (Figure 13A). Given that gp33 does not appear to be responsible for the induction 
of whiB7 in the BPs-M. chelonae lysogen, these findings are not surprising. It can be 
concluded that gp33 is not responsible for the increased antibiotic resistance of M. chelonae 
in the presence of the BPs prophage.  
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 Although gp5 appears to be a lytic gene, we wondered if co-expression of gp5 and 
gp33 would impact gp33 expression levels. We were intrigued by BPs gp5 because of its 
predicted function as a ribosome modulation factor. Ribosome modulation factors stabilize 
70s ribosomes to more efficiently initiate translation of leaderless transcripts, like the gp33 
transcript (Broussard et al., 2013, Beck, H., Moll, I., 2018). Leaderless transcripts lack 
ribosome binding signals and binding of the 70s ribosome to the 5′ terminus stabilizes the 
mRNA and protects the transcript from degradation (Beck, H., Moll, I., 2018). Therefore, 
gp5 could potentially stabilize the gp33 transcript. The episomal plasmid expressing gp5 
is maintained by a parABS system (Dedrick et al., 2016). In the presence of pMHIR, the 
gp5 plasmid is unstable, indicating that the two plasmids are incompatible. Both plasmids 
were detectable at the beginning of culture growth, but the gp5 plasmid was lost just prior 
to RNA isolations. We were still able to observe an increase in gp33 expression in M. 
chelonae (pMHIR) strains carrying the gp5 plasmid (Figure 14). This effect was not 
observed in M. chelonae (pMHIR) strains carrying the empty plasmid vector for gp5. It is 
possible that gp5 protein produced prior to loss of the plasmid remained in cells after loss 
of the plasmid and had an effect on gp33 expression. Co-expression of gp5 and gp33 in M. 
chelonae does not lead to decreased padR expression levels (Figure 15), again suggesting 
that gp33 most likely does not play a role in padR regulation.  
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CONCLUSIONS & FUTURE WORK 
 
 
 
This thesis project has contributed to the overall understanding of the role of 
prophage in the gene expression and antibiotic resistance of their bacterial hosts. My work 
has helped the Molloy lab determine that gp33 expression is likely not responsible for 
changes in whiB7 expression. Since the completion of this work, the Molloy lab has 
determined that a naturally occurring prophage must be present with the BPs prophage to 
change expression of whiB7. My work has helped to show that BPs lysogenic gene 
expression is not important for this interaction. Given that all cultures of bacterial lysogens 
contain a subset of cells undergoing induction (lytic phage infection), we are currently 
looking at the role of BPs lytic gene expression in the presence of the naturally occurring 
prophage as means of altering bacterial gene expression.  
Future work will also investigate the roles of other prophage-encoded genes to 
determine if the expression of other virally-encoded genes is necessary to impact M. 
chelonae gene expression and antibiotic resistance. More work needs to be done to 
determine the impact of gp33 expression on padR. Our lab is currently using a GFP reporter 
plasmid under the control of the padR promoter to determine the impact of gp33 on 
expression. The strains I produced in this work will be used to test GFP expression in the 
presence or absence of gp33. Recombinant strains of M. chelonae lacking padR or whiB7 
or overexpressing padR or whiB7 could be created to determine their respective effects on 
antibiotic resistance. Further analyses can be performed on the M. chelonae recombinant 
strain, M. chelonae (pMHIR), expressing gp5 to determine if co-expression of BPs genes 
gp33 and gp5 is needed to cause differential expression of M. chelonae whiB7 and 
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increased antibiotic resistance. The mobile genetic element of BPs, gp58, can also be 
transformed into M. chelonae to investigate its impact on M. chelonae gene expression. 
Overall, the outcome of this thesis was crucial to helping rule out lysogenic gene expression 
from prophage BPs as a driver of whiB7 expression in M. chelonae. 
In conclusion, understanding the interaction between phage and their bacterial hosts 
is crucial to understanding antibiotic resistance mechanisms and treating antibiotic resistant 
infections. The work of my thesis has directly helped us understand more about how phage 
contribute to antibiotic resistance. But phage can also be used to treat infections that are 
completely resistant to antibiotics. In fact, a young cystic fibrosis patient who was fatally 
ill with an M. abscessus infection was successfully treated with a cocktail of genetically 
engineered phage, including BPs (Dedrick et al., 2019, Dedrick et al., 2019 
(B)).  Furthering our understanding of bacterial resistance mechanisms, including 
prophage, will provide insight into alternative therapeutics for antibiotic resistant 
infections, like phage therapy.  
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